Santen Pharmaceutical (OTCMKTS:SNPHY) Trading Up 6.6% – Time to Buy?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) shares traded up 6.6% on Wednesday . The stock traded as high as $11.9620 and last traded at $11.9620. 521 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 13,901 shares. The stock had previously closed at $11.22.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a research report on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the stock has a consensus rating of “Hold”.

Santen Pharmaceutical Trading Up 6.6%

The firm has a market capitalization of $3.86 billion and a PE ratio of 0.10. The firm has a 50-day moving average of $11.27 and a two-hundred day moving average of $10.88.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.